Bhaumik H. Trivedi’s Post

Understanding the signs and symptoms of fatty liver disease is crucial for early diagnosis and treatment. Learn from Dr. Pawan Rawal, a leading gastroenterologist in India, about the key indicators and the importance of specialized care. Discover more about how advanced liver clinics can help you manage and improve liver health. #FattyLiverDisease #Gastroenterology #LiverHealth #DrPawanRawal #AdvancedLiverClinic #HealthcareIndia

The Critical Link Between Metabolic Health & Liver Health. Did you know that metabolic health plays a key role in liver function? With the rise in conditions like obesity, diabetes, and metabolic syndrome, our livers are facing an increasing burden. Poor metabolic health can lead to the development of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which often goes unnoticed in its early stages. Early detection is crucial. Liver diseases like MASLD can progress silently for years, potentially leading to more severe conditions such as cirrhosis or liver cancer if left untreated. This is where LIVERFASt play an important role. Our non-invasive diagnostic tool is designed to provide accurate assessments of liver health, detecting issues before they become critical. By helping healthcare providers monitor liver function and detect early signs of liver disease, LIVERFASt empowers proactive management and better health outcomes. Prioritize your metabolic health for the sake of your liver. Early detection saves lives. #LiverHealth #MetabolicHealth #LiverDisease #EarlyDetection #liverfast Reference: Younossi, Z. M., et al. (2018). Non-alcoholic fatty liver disease: A global public health perspective. Nature Reviews Gastroenterology & Hepatology, 15(5), 323-335.

🌟 Exciting News Alert! 🌟 Recent study suggests daily low-dose aspirin could be a game changer for people with nonalcoholic fatty liver disease (NAFLD). 🩺💊 Researchers found that after just 6 months, liver fat levels decreased significantly in those taking baby aspirin compared to a placebo group. 📉 Plus, over 40% of participants saw their liver fat drop by more than 30%! 💥 While more research is needed before recommending aspirin for everyone with NAFLD, the potential benefits are promising. 💪 Learn more about this study and its implications below! #Health #LiverHealth #AspirinResearch https://bit.ly/497HX1v

As its Rare Disease Day, dive into the intricate realm of Primary Biliary Cholangitis (PBC), a chronic liver disease marked by immune-mediated bile duct damage. Here is a snapshot from a recent discussion at the AASLD 2023 Liver Meeting, shedding light on the nuances of this condition: 🌟 Cholestatic Pruritus Unveiled: Meet the often-overlooked companion of PBC - Cholestatic Pruritus. It's not just an itch; it's a persistent, deep sensation that evolves throughout the day, affecting up to 81% of PBC patients. 🌟 Impact on Quality of Life: Cholestatic pruritus isn't merely a physical discomfort. It's a game-changer for Health-Related Quality of Life (HRQoL), introducing sleep disturbances, mood swings, and even social isolation. 🌟 Recognition Matters: Despite its prevalence, cholestatic pruritus often hides in the shadows of clinical discussions. Healthcare professionals play a crucial role in recognizing and assessing this symptom using tools like numerical rating scales and innovative patient-tracking apps. Let's join hands to foster awareness, understanding, and support for those navigating the complex landscape of PBC. Together, we can enhance patient care, improve diagnostics, and unravel the mysteries of this intriguing condition! 💪🔬 #PBCAwareness #LiverHealth #MedicalInsights #HealthcareInnovation 🌐✨ The publication of this article was supported by GSK. #pbc #aasld #easl #hepatology #rarediseaseday #raredisease #rarediseaseawareness #emjinspire #itch #learning #gastroenterology #education https://lnkd.in/eqVUZ2py

Interesting news in the world of liver research! A recent editorial by Dr. Jian-Gao Fan and Dr. Lu Jiang from Xinhua Hospital underscores the pivotal role of gut microbiota in various liver diseases, emphasizing the need for microbiota-based therapeutic interventions. The "gut-liver axis" special issue delves into the contribution of gut microbiota to chronic liver conditions, suggesting that advances in microbiome research may lead to personalized treatments. Read more about it below! #liverdisease #patientcare #healthcare #microbiome https://lnkd.in/gmCSgwJ2

Non-alcoholic fatty liver disease (NAFLD) and irritable bowel syndrome (IBS) are the two most common gastrointestinal disorders in the general population, presenting significant challenges to healthcare systems and impacting the quality of life for millions of people. Some studies highlight a direct link between both since there are common mechanisms involved in many of the local and systemic manifestations of NAFLDs and IBS leading to shared risk factors. The interrelationship between these two conditions remains an area of active research, with a growing interest in understanding how they might influence each other, the implications for patient management, and potential treatment strategies. This article aims to provide a comprehensive exploration of both NAFLD and IBS, delving into their individual characteristics and examining the connections between them. Understanding these connections will help guide healthcare providers in delivering effective care and support to those affected by these chronic conditions.

With #FattyLiverDisease continuing to climb at an alarming rate, we need to empower the most accessible healthcare providers – including pharmacists, who play a crucial role in managing fatty liver disease by offering self-care tips, treatment access, and medication management. Dr. Catherine Duggan contributed as a panelist at the joint Global Liver Institute and EASL | The Home of Hepatology event to assesses successful #liverhealth approaches to inform and encourage effective policies worldwide, entitled “Together for Better Liver Health: Amplifying Best Practices Globally.” Dr. Duggan expanded on GLI's "Liver Health is Public Health" report – which emphasizes the importance of early intervention, regular screenings, and a collaborative approach between healthcare professionals and patients – with an article focused to how pharmacies could get invovled to cobatting #liver diseases. To reverse the trend in liver disease and improve outcomes, liver health must be prioritized at both #policy and practice levels, focusing on #prevention and early treatment. Pharmacists can support this effort by screening high-risk patients, providing reliable information, and promoting self-care to help detect and manage #fattyliver disease early. Read the full article with the link below: 📖 https://lnkd.in/e2wRkmfH #WHA77 #Geneva #health #healthcare #livercommunity #liverstrong #LiverHealthIsPublicHealth

After an announcement on behalf of multinational liver societies last year, non-alcoholic fatty liver disease (NAFLD) is diagnosed and recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). Experts from 50 countries convened in a two-year process that resulted in new categories and terminologies for multiple liver diseases and conditions, which they argued were more accurate and could help the field of liver study get specific about its patient populations. With researchers, medical journals, regulatory bodies and advocacy groups already widely adapting the new terminology for their own uses, STAT notes that the true challenge of the transition will now be educating patients and providers about the names.    While there are no treatments approved for metabolic dysfunction-associated steatohepatitis (MASH; formerly non-alcoholic steatohepatitis) or MASLD, a strong focus on research continues with two new investments from major industry players announced this week alone. #MASH #MASLD #LiverDisease

🧐Check out #Review: New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis 🎓 by Dr. Grigorescu Elena-Daniela. Dr. Cristina Lacatusu et al., from Grigore T. Popa University of Medicine and Pharmacy Iași 📄Enjoy reading: https://lnkd.in/e23W2ctN #non-alcoholic fatty liver disease; #coronary artery disease; #cardiovascular risk; #liver-heart axis

Discover the Hidden Secrets of the Arnolfini Portrait: Free Webinar on NAFLD with Michael Ash! Join us for a captivating and educational free webinar on Nonalcoholic Fatty Liver Disease (NAFLD), presented by Michael Ash. Uncover how the enigmatic symbols in the Arnolfini portrait from 1434 reveal mechanisms and solutions to the global rise of NAFLD. Register for Free: https://lnkd.in/esE5CyM5 About the Presentation: Your liver is a vital organ, performing numerous critical functions such as converting food into fuel, processing fats, clearing toxins, and producing proteins for blood clotting. Despite its importance, the liver is vulnerable to NAFLD, a serious and often undiagnosed condition. While no drug treatments exist for NAFLD, early intervention can stop and even reverse its effects. This webinar will delve into: 🔍 The mechanisms behind NAFLD 🔍 Strategies to reduce, prevent, and reverse fatty build-up in the liver 🔍 The hidden symbols in the Arnolfini portrait that connect to NAFLD solutions About the Presenter: Michael Ash DO, ND, BSc, RNT has been a healthcare provider since 1982. For 25 years, he led the Eldon Health Clinic, one of the largest interdisciplinary clinics in southwest England. Michael is renowned for translating complex immunological and functional medicine concepts into practical strategies for patient care. Why Attend? Gain a deep understanding of NAFLD and its management Learn practical strategies to support liver health Discover the fascinating connection between art and medicine   Don’t miss this unique opportunity to learn from a leading expert in functional medicine. Register now and take the first step towards better liver health! #NAFLD #LiverHealth #FunctionalMedicine #FreeWebinar #ClinicalEducation #MichaelAsh #ArtAndMedicine